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Abstract
BACKGROUND & AIMS—Little is known about the incidence of drug-induced liver injury 
(DILI) and risk factors for adverse outcomes. We evaluated short-term outcomes of a large cohort 
of patients with DILI enrolled in an ongoing multicenter prospective study.
METHODS—Data were collected from 660 adults with definite, highly likely, or probable DILI. 
Regression methods were used to identify risk factors for early liver-related death or liver 
transplantation and chronic liver injury.
RESULTS—Patients’ median age was 51.4 years; 59.5% were female and 59.1% required 
hospitalization. Within 6 months of DILI onset, 30 patients received liver transplants (4.5%; 95% 
confidence interval [CI], 3.0%–6.1%) and 32 died (5%; 95% CI, 3.2%–6.5%); 53% of the deaths 
were liver related. Asian race, itching, lung disease, low serum albumin levels, low platelet counts, 
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and high serum levels of alanine aminotransferase and total bilirubin at presentation were 
independent risk factors for reduced times to liver-related death or liver transplantation (C-statistic 
= 0.87). At 6 months after DILI onset, 18.9% of the 598 evaluable subjects had persistent liver 
damage. African-American race, higher serum levels of alkaline phosphatase, and earlier heart 
disease or malignancy requiring treatment were independent risk factors for chronic DILI (C-
statistic = 0.71).
CONCLUSIONS—Nearly 1 in 10 patients die or undergo liver transplantation within 6 months 
of DILI onset and nearly 1 in 5 of the remaining patients have evidence of persistent liver injury at 
6 months. The profile of liver injury at presentation, initial severity, patient’s race, and medical 
comorbidities are important determinants of the likelihood of death/transplantation or persistent 
liver injury within 6 months.
Keywords
Hepatotoxicity; Acute Liver Failure; Transplantation; Causality
Drug-induced liver injury (DILI) is an infrequent cause of liver disease in the general 
population and accounts for <1% of hospitalized patients presenting with jaundice.1,2 
Nonetheless, DILI is a leading reason for regulatory actions involving investigational and 
approved medications and is also a leading cause of acute liver failure in the United 
States.3,4 Because of its low incidence and the difficulty in establishing a diagnosis, the 
natural history of DILI is not well described. One frequently cited report suggested that 
prolonged medication administration and inadvertent drug rechallenge might be risk factors 
for developing chronic DILI.5 In addition, DILI patients with cholestatic liver injury might 
have a slower rate of biochemical improvement and be at increased risk for developing 
chronic liver disease.6,7 However, the number of patients reported in earlier studies was 
limited and variable criteria for chronic DILI were used.6-8
The Drug-Induced Liver Injury Network (DILIN) consists of 8 academic medical centers 
and a data-coordinating center sponsored by the National Institutes of Health. In 2004, a 
prospective registry study of patients with suspected DILI was initiated to improve our 
understanding of the etiology, risk factors, and natural history of DILI in the United 
States.8,9 Subjects with liver injury that persists for at least 6 months after DILI onset are 
followed for 2 years to better define their long-term outcomes. In the initial analysis of the 
first 300 patients enrolled in the DILIN database, 15% of the subjects met predefined 
laboratory, clinical, and/or radiographic criteria for chronic DILI at 6 months after 
presentation.10 In the current analysis, we set out to determine the short-term (6 month) rates 
of death, liver transplantation, and chronic DILI of the first 660 evaluable adult patients 
enrolled in the DILIN prospective study with definite, highly likely, or probable DILI. In 
addition, we set out to identify risk factors at presentation for early death or liver 
transplantation as well as for self-limited vs chronic DILI.
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Drug-Induced Liver Injury Network Prospective Study
The protocol for this multicenter observational study was approved by the Institutional 
Review Boards at each clinical site and all enrolled subjects provided written informed 
consent. DILI onset was defined as the first date after a subject taking any medication or 
herbal and dietary supplement (HDS) met the predefined laboratory criteria for study entry. 
Specifically, all subjects had to have a serum aspartate aminotransferase (AST) or alanine 
aminotransferase (ALT) level that exceeded 5× the upper limit of normal (ULN) (or 5× 
pretreatment baseline if baseline abnormal), a serum alkaline phosphatase (ALP) that 
exceeded 2× the ULN (or 2× pretreatment baseline if baseline abnormal), a total bilirubin 
>2.5 mg/dL, or an international normalized ratio (INR) >1.5 on 2 consecutive blood draws. 
All study participants were older than 2 years of age and had to be enrolled within 6 months 
of DILI onset. Patients with known or suspected acetaminophen hepatotoxicity, autoimmune 
hepatitis, or primary sclerosing cholangitis, or a history of a bone marrow or liver 
transplantation before DILI onset were excluded.
A detailed medical and medication history was obtained at the baseline study visit and 
additional laboratory and radiologic testing was performed to more fully characterize the 
DILI event and exclude competing etiologies. All enrolled patients were seen for a follow-
up study visit at 6 months after initial enrollment and those with evidence of chronic DILI 
within 6 months of DILI onset were asked to return for additional follow-up visits at 12 and 
24 months. Chronic DILI was defined as having a persistently elevated serum AST, ALT, 
ALP, or total bilirubin level, histologic evidence of ongoing liver injury, or radiologic 
evidence of persistent liver injury (ie, ascites on imaging) at 6 months or more after the 
initial DILI onset date.9,10 The causal relationship between the liver injury episode and the 
implicated agent(s) was evaluated in a standardized fashion by the DILIN causality 
committee.11 A DILIN causality score varying from 1 (Definite >95% likelihood), 2 (Very 
Likely 75%–95% likelihood),3 (Probable 50%–74% likelihood), 4 (Possible 25%–49% 
likelihood), to 5 (unlikely <25% likelihood) was assigned by consensus agreement of 
committee members. In subjects with 2 or more implicated drugs, an overall causality score 
was assigned to the case and then an individual causality score for each drug was given. For 
cases with multiple implicated HDS products (with or without implicated drugs), an overall 
causality score was assigned to the case and then a causality score for each individual drug 
and one overall HDS causality score for all HDS products was assigned. Only the overall 
causality score for the case was used for reporting. A primary implicated agent was assigned 
to each case as the agent with the highest individual causality score or the one with higher 
ranking by site if ties occur. A 3-tiered nested system was used in DILIN to classify the 
primary implicated agents into primary (overall class), secondary (based on use), and 
tertiary (based on chemical class). In addition, the severity of the DILI episode was 
categorized on a 5-point scale from mild (1), moderate (2), moderate-hospitalized (3), severe 
(4), and fatal (5), where a fatal score was assigned only if the patient died or had liver 
transplantation due to DILI. Before April 2009, causality was assessed from baseline data 
and a clinical narrative. After April 16, 2009, accrued 6-month follow-up data were included 
in the causality assessment, which involves 485 of the 660 patients in this study. All deaths 
Fontana et al. Page 3






















in DILIN patients were classified by clinical site as liver-related or not. The enrolled cases 
with an overall causality score of “possible” (4) or “unlikely” (5) or not adjudicated yet were 
excluded from the current analysis, as were children (n = 36). To identify predictors of 
chronic liver injury, subjects with known pre-existing chronic hepatitis B virus/hepatitis C 
virus (n = 28) were also excluded from this analysis, as were subjects whose chronic status 
could not be determined due to dropping out of study before completing their 6-month study 
visit (n = 77).
Statistical Methods
Descriptive statistics, mean with SD or median with range, were used to describe continuous 
variables, and frequency and percent were used to describe categorical variables. A 
nonparametric test, Wilcoxon or Kruskal-Wallis test, was used for comparison of 2 or 3 
groups for continuous variables, and χ2 test for comparison between groups for categorical 
variables. Data for early outcomes (non–liver-related death, liver-related death, or liver 
transplantation) within 6 months of DILI onset were first described and modeled. Then, data 
for chronic status at 6 months after DILI onset were described and modeled. Demographic 
and clinical data at DILI onset or between onset and 6 months from onset were extracted to 
describe and compare 2 groups with and without 2 early outcomes of interest: death or 
transplantation within 6 months and chronic DILI at 6 months after DILI onset. Death was 
subcategorized as liver or non–liver-related and descriptive statistics were used to describe 
and compare the 3 early adverse events: liver transplantation, liver-related death, and non–
liver-related death. Cox regression hazard models were used for time to early event analyses 
where an early event is defined as death or liver transplantation within 6 month of onset. 
Clinically, it makes more sense to consider only liver-related early event, rather than 
lumping all death and liver transplantations together. Time to early liver-related event (liver-
related death or liver transplantation) was also performed. Logistic regression was used to 
model the binary outcomes of chronic status. All model selection used an initial univariate 
analysis to screen potential candidates for multivariate modeling. Variables with a univariate 
P value ≤.1 were considered. For variables with known co-linearity or high correlation, 
clinical judgment was used to select one predictor for additional modeling, for example, 
jaundice and total bilirubin are highly related and only total bilirubin was used in the 
multivariate modeling due to its clinical objectivity. Stepwise selection procedure was used 
to derive the final models and the results reported either as hazard ratio or odds ratio (OR) 
with 95% confidence interval (CI), C-statistic was used to describe the fit of the final 
models.
The following potential predictors were considered in the modeling for both outcomes of 
interest: demographic variables (age, sex, race, weight, body mass index) at baseline visit, 
signs and symptoms at DILI onset (except jaundice), medical history, latency, duration of 
primary agent use, laboratory parameters (white blood cell count, absolute eosinophil count, 
platelets, serum creatinine, antinuclear antibodies, anti-Smith antibodies) at DILI onset, liver 
biochemistries (ALT, ALP, total bilirubin, Hy’s law, INR, albumin, hemoglobin) at DILI 
onset. Predictor variables with >50% missing data were not considered further in the 
modeling. Analyses were carried out on subjects without missing outcomes data, with the 
assumption that there were no differences between the subjects with and without outcomes 
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data. Subjects with and without known early outcomes were compared in terms of 
characteristics to assess whether the data are missing at random. Due to multiple 
comparisons with a large number of variables, we assume that data are missing at random if 
we observed <5% of significant differences at.05 level. All P values reported are 2-sided 
and a level of .05 or less is considered statistically significant. All data were analyzed by 
SAS software (version 9.2, SAS Institute, Inc, Cary, NC).
Results
Patient Population
There were 991 patients enrolled in the DILIN prospective registry from September 2004 
through July 31, 2011, which included 801 patients that were adjudicated as definite, highly 
likely, or probable DILI (Figure 1). Of the 801 DILI patients, an additional 141 patients 
were excluded from this analysis due to age younger than 18 years (n = 36), pre-existing 
chronic hepatitis B or C infection (n = 28), or with missing chronic status due to dropping 
out of the study before 6 months follow-up (n = 77). Of the remaining 660 patients, there 
were 62 patients who either died (n = 32) or underwent liver transplantation (n = 30) within 
6 months of DILI onset. Therefore, 598 total adult DILIN patients had data available at 
baseline and 6 months after DILI onset for analysis of chronic DILI risk factors. Of note, the 
clinical and presenting features of the 77 patients with incomplete follow-up were not 
significantly different from the 660 patients included in this analysis, except that the 
excluded patients were significantly younger and more likely to be Hispanic (data not 
shown). Sensitivity analyses assessing impact of missing data in these 77 subjects were not 
performed.
Death and Liver Transplantation Within 6 Months of Drug-Induced Livery Injury Onset
Table 1 provides a descriptive summary of the presenting features of the 62 patients who 
died or underwent liver transplantation compared with the 598 subjects without these events 
by month 6. A total of 30 patients (4.5%; 95% CI, 3.0%–6.1%) underwent transplantation 
and 32 (5%; 95% CI, 3.2%–6.5%) died; 53% of the deaths liver related. Among subjects 
with an acute hepatocellular injury (ie, R > 5), the percent of early death/transplantation was 
13% (95% CI, 9%–17%) compared with 6% (95% CI, 3%–9%) in those with a mixed or 
cholestatic injury profile. Subjects who died or underwent transplantation were significantly 
more likely to be Asians and to have underlying diabetes mellitus, lung disease, and various 
other medical comorbidities. These 62 patients had similar clinical symptoms at presentation 
compared with those that survived, but their total white blood cell counts at presentation 
were significantly higher and mean eosinophil count at DILI onset was lower. As expected, 
subjects who died or underwent transplantation had higher mean serum ALT, total bilirubin, 
INR, and Model for End-Stage Liver Disease scores compared with those who survived.12 
In addition, these patients were more likely to have severe acute hepatocellular injury with a 
higher median R value at presentation (11.0 vs 5.1; P < .01). In addition, the proportion of 
patients that met Hy’s law criteria (ie, serum ALT >3× ULN, ALP <2× ULN, and total 
bilirubin >2× ULN) was greater in those with transplantation/fatal outcomes compared with 
the survivors (45.8%vs 26.2%; P < .01). Patients with early adverse outcomes were also 
more likely to have received corticosteroids, and use of ursodeoxycholic acid was similar in 
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both groups. Interestingly, the causality scores of those with early adverse outcomes who did 
not improve during follow-up were, as a group, lower compared with those who survived.
Median duration of suspect medication use was significantly longer in those with an early 
adverse outcome compared with the survivors (67 vs 31 days; P = .02). Although there were 
many different implicated drugs and HDS products, anti-neoplastic drugs were significantly 
more commonly reported in those with early adverse outcomes (Table 1).
Among the 62 subjects with an early adverse outcome, 32 patients died; 17 (53%) of the 
deaths were judged to be liver related, and the remaining 15 were attributed to nonhepatic 
causes. The Kaplan-Meier curves for time to non–liver-related death, liver-related death, and 
liver transplantation are presented in Figure 2 with event rates of 2.5%, 2.8%, and 4.8% at 6 
months from onset, respectively. Mean time from DILI onset to liver-related death was 56 ± 
48 days (range, 5–171 days), to non–liver-related death was 76 ± 51 days (range, 16–171 
days), and to liver transplantation was 35 ± 28 (range, 2–131 days). Other important 
differences between these groups are shown in Table 2. First, the subjects who died of a 
nonhepatic cause were more likely to have active medical comorbidities, including heart 
disease and cancer, and a significantly lower body mass index compared with the other 2 
groups. Of interest, 33% of these patients were being treated for cancer with an anti-
neoplastic drug implicated in the DILI event. In contrast, the patients who underwent liver 
transplantation were significantly younger (mean age, 47 years; range, 21–73 years) and 
were less likely to have medical comorbidities. In addition, liver transplant recipients had 
significantly higher initial and peak serum AST, ALT, and R values compared with the other 
2 groups. In fact, 96.7% of transplant recipients had a hepatocellular liver injury pattern at 
DILI onset compared with 64.7% in those with a liver-related death, and only 26.7% of 
those who died of nonhepatic causes. In addition, there was a trend toward higher INR and 
bilirubin levels at presentation compared with the other 2 groups. Not surprisingly, the 
transplant recipients were more likely to meet Hy’s law criteria compared with the other 2 
groups (63.0%vs 35.3% and 26.7%). The DILIN causality scores were similar in the 3 
groups. The most frequently implicated drugs in the transplanted patients were 
antimycobacterial agents, followed by HDS products, which, when combined, accounted for 
73% of the transplanted patients (Supplementary Table 1).
Presenting Features Associated With Early Liver-Related Death/Liver Transplantation
Two multivariate models were fit to time to event data, one for time to death/transplantation 
and the other for time to liver-related death/transplantation. Both final models yielded the 
same predictors except the malignancy variable was in the final model for time to all death/
transplantation, but not in the final model for time to liver-related death/liver transplantation. 
Due to clinical relevance, only the later model is presented in Table 3. On multivariate 
analysis, subjects of Asian race and those presenting with lower serum albumin levels, lower 
platelet counts, higher serum ALT and bilirubin levels, and those with underlying 
pulmonary disease and without itching were significantly more likely to experience a liver-
related death or to undergo transplantation. The C-statistic for the overall model fit was 0.87 
(Table 3). Asian race remained an independent risk factor even after considering 
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antimycobacterial agent use because there was no association between Asian race and 
antimycobacterial agent use.
Chronic Drug-Induced Liver Injury Cohort Analysis
Among the 598 patients with available 6-month follow-up data, there were 113 patients 
(18.9%) who met at least 1 of the 6 protocol-defined criteria for chronic DILI. The 6 specific 
criteria met in these patients were persistent serum AST, ALT, or ALP levels above baseline 
in 97 patients, liver function test 1.25× baseline on 2 occasions in 6, portal hypertension 
after 6 month from DILI onset in 8, radiologic evidence of chronic DILI in 23, histologic 
evidence of chronic DILI in 6, and clinical evidence of chronic DILI in 36. Forty-three 
(38.1%) of the subjects met more than 1 criteria for chronic DILI. There were several 
important baseline differences in those who did and did not go on to develop chronic DILI 
(Table 4). Although the mean age and percent female were similar, those with chronic DILI 
were significantly more likely to be African American (18.6%vs 8.7%; P < .01). The clinical 
symptoms at presentation were similar between the 2 groups, but chronic DILI patients were 
significantly more likely to have a malignancy requiring treatment and 13 were receiving an 
anti-neoplastic suspect drug. Median duration of medication use was also significantly 
longer in those that developed chronic DILI compared with those who did not (51 vs 30 
days; P < .01).
The chronic DILI patients were more likely to have cholestatic liver injury at presentation, 
with significantly higher initial and peak serum ALP levels and lower serum albumin levels 
compared with those that did not develop chronic DILI (Table 4). Although the presenting 
total bilirubin and INR levels were similar, the chronic DILI patients had a significantly 
higher peak total bilirubin and INR levels during follow-up, consistent with a more severe 
liver injury episode. In support of this, the mean DILIN severity scores were significantly 
higher (or worse) in those with chronic DILI compared with those without chronic DILI. 
Not surprisingly, corticosteroids were also more commonly used in those that went on to 
develop chronic DILI compared with the others.
Presenting Features Associated With Chronic Drug-Induced Liver Injury
Multivariate modeling was used to investigate independent laboratory and clinical features 
at presentation for developing chronic DILI. When we included potential predictors at 
presentation that were associated with a greater likelihood of chronic DILI (ie, P < .10), the 
presenting serum ALP, African-American race, active malignancy, and heart disease, were 
independent predictors of chronic DILI (C-statistic = 0.71; 95% CI, 0.65–0.76) (Table 5).
Discussion
This prospective, multicenter observational study provided a unique opportunity to identify 
presenting clinical and laboratory features associated with the most serious outcomes of 
DILI (ie, death or liver transplantation), in a large cohort of well-characterized American 
patients. As noted in Figure 1, thirty-two subjects died and 30 subjects underwent liver 
transplantation within 6 months of DILI onset. Of note, only 53% of the deaths were 
attributed to progressive liver injury, and the remaining subjects died of various nonhepatic 
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causes. Liver-related deaths occurred within 1 month of DILI onset in most patients, and the 
non–liver-related deaths tended to occur at a median of 2 months. These data clearly 
demonstrate that idiosyncratic DILI in the United States is associated with significant 
morbidity and mortality. The 9.4% rate of death/transplantation is higher than the rates of 
adverse outcomes reported from DILI registries in Spain and Sweden (4% and 9.2%, 
respectively).13,14 The higher observed rates are not likely due to more severe liver injury at 
enrollment, but rather the prospective tracking of patients enrolled in the DILIN protocol. 
The suspect agents associated with the 17 liver-related deaths included a multitude of 
antibacterial antibiotics (47%) and other agents, and the drugs implicated in the 15 subjects 
with non–liver-related deaths were more likely to be anti-neoplastic agents (33%) 
(Supplementary Table 1). For unclear reasons, subjects who died or underwent liver 
transplantation were more likely to be Asian compared with those who survived. Of note, 
earlier studies have also demonstrated an over-representation of racial/ethnic minorities 
among subjects with severe DILI.15,16 Whether these observations are due to increased 
susceptibility, delayed presentation, or impaired liver regeneration among Asians remains 
unknown, but they are worthy of additional study. Of note, subject age, sex, and recent 
alcohol consumption did not differ among those with and without early adverse outcomes, 
suggesting that these factors, which are used in many scoring systems, might not be 
associated with short-term outcomes. Subjects with early death/transplantation were more 
likely to have diabetes mellitus and several other medical comorbidities on univariate 
analyses. The increased mortality among diabetics might be due to the greater prevalence of 
underlying fatty liver disease or increased susceptibility to infections or other complications 
of severe acute liver injury.17 However, diabetes and other comorbidities were not 
significant in the multivariate model, except pulmonary disease (Table 3). The reason for 
increased mortality in subjects with underlying lung disease is unclear. However, among 15 
subjects with lung disease who died or underwent liver transplantation, only 4 received INH 
and 3 had latent tuberculosis, and only 1 had active tuberculosis.
Our data confirm that DILI patients with laboratory evidence of more severe liver injury at 
presentation (ie, higher serum ALT and bilirubin levels), as well as during their illness, are 
more likely to experience adverse outcomes during short-term follow-up. Descriptive 
summary data showed that those with poor early outcomes were also more likely to have 
received corticosteroids, presumably in an attempt to salvage their severely damaged livers, 
although they were not more likely to have evidence of hypersensitivity features (eg, rash, 
fever, eosinophilia) at presentation. Interestingly, subjects with adverse outcomes were also 
more likely to have been treated with the suspect agent for a longer period of time compared 
with those with self-limited DILI, but the specific suspect agents differed in the 2 
groups.18,19 It is possible that these individuals might have had liver injury for a longer 
period of time before discontinuation of the suspect medication. The larger proportion of 
cases due to antineoplastic agents suggest that these agents might be particularly prone to 
cause severe DILI.15,16 Our data also confirm that subjects with severe acute hepatocellular 
injury or those who meet Hy’s law criteria are more likely to experience adverse outcomes. 
However, 29.4% of those who died of liver-related cause had a cholestatic liver injury 
pattern at presentation. The lower causality scores in the patients with early death/
transplantation might be due, in part, to the lack of improvement in laboratory parameters 
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after drug discontinuation (ie, “positive dechallenge”), which is used as supporting evidence 
in DILI diagnosis. A similar finding was previously noted in patients with fulminant DILI.20
The 30 subjects who required liver transplantation were significantly younger and less likely 
to have an active malignancy compared with those who died. These observations are in 
keeping with other studies in which subjects with an anticipated likelihood of long-term 
survival are more likely to undergo transplantation. The most commonly implicated agent in 
the liver transplant recipients was isoniazid, followed by various other agents. Interestingly, 
nearly one third of the transplantation cases were due to HDS hepatotoxicity without a 
dominant HDS being implicated (Supplementary Table 1). These data suggest that 
additional studies of this increasingly recognized cause of severe hepatotoxicity are needed, 
including a careful analysis of their constitutive ingredients.21
With a minimum of 6 months post-enrollment follow-up, 131 patients were adjudicated as 
possible DILI, and 48 patients were adjudicated as unlikely DILI, representing 18.1% of the 
enrolled patients. These data highlight the continued difficulty in making an accurate 
diagnosis of DILI.8,9 This observation also confirms that a comprehensive series of 
diagnostic tests should be obtained in all patients with suspected DILI, including tests for 
acute hepatitis C virus, hepatitis E virus, and Epstein-Barr virus infection.22-24
The 18.9% (95% CI, 15.8%–22.0%) rate of chronic or persistent liver injury at 6 months of 
follow-up is substantially higher than the 5.7% incidence reported by other groups, which 
might be due to our longer period of follow-up and high retention rate of enrolled subjects.18 
However, the severity of residual liver injury was mild in most patients, with median AST, 
ALT, and ALP levels of only 63, 75, and 178, respectively, at the 6-month study visit. In 
addition, only 39.6% of these subjects had a serum bilirubin level >1.0 mg/dL at the 6-
month study visit. Of note, the median duration of suspect medication use was longer in 
those who developed chronic DILI, which is consistent with earlier studies.18,19 In addition, 
subjects with a higher serum ALP and lower serum albumin levels at presentation were at 
increased risk of developing chronic DILI.18,19 In addition, the peak ALP, bilirubin, and 
INR levels were significantly higher in those who developed chronic DILI, indicating that 
subjects with more severe liver injury were more likely to develop persistent liver injury. 
This is corroborated by the higher mean DILIN severity score and the larger proportion of 
chronic DILI patients who required hospitalization compared with those with self-limited 
injury (66.4%vs 52.6%; P = .008).
On multivariate analysis, African Americans were more likely to develop chronic DILI 
compared with other racial groups. Earlier studies of anticonvulsant hepatotoxicity have 
shown a similar trend of poorer outcomes among African Americans, which might be 
immunologically mediated.25 Subjects with an active malignancy were also more likely to 
develop chronic DILI, which might be due, in part, to cancer patients being followed more 
carefully and frequently (detection bias), having liver involvement by the primary cancer, or 
from continued use of a potentially hepatotoxic medication in a high-risk setting. Finally, 
subjects with higher serum ALP levels at presentation were more likely to develop chronic 
DILI. Earlier studies have suggested a slower rate of biochemical improvement in subjects 
with a cholestatic drug reaction, and our large, prospective dataset strengthens this important 
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observation.19 Of note, subjects with higher bilirubin levels at presentation were also more 
prone to develop chronic DILI. These observations indicate that those who present with 
severe cholestatic DILI or require hospitalization might need more frequent and careful 
follow-up. Chronic DILI patients were also more likely to receive corticosteroids, despite 
the fact that they did not have more frequent eosinophilia, autoantibodies, or rash at 
presentation (Table 4). Unfortunately, our observational data do not allow us to determine if 
corticosteroid use hastened the resolution of liver injury and this important question requires 
additional study.
Strengths of our study include the fact that this was a prospective observational study carried 
out at 8 geographically distinct sites. In addition, subjects of varying age, sex, and ethnicity 
with a broad spectrum of liver injury severity due to a multitude of drugs and HDS products 
were enrolled, which strengthened the generalizability of our findings. From a diagnostic 
perspective, all of the subjects underwent a thorough evaluation for competing causes of 
liver injury and were followed for a minimum of 6 months after DILI onset and a rigorous 
causality assessment was undertaken in a standardized manner.11 This latter point was 
particularly important because a modest proportion (18.1%) of the enrolled patients were 
finally adjudicated as having only possible or unlikely DILI during follow-up. This study 
also represents the largest cohort of DILI patients reported to date and provided the 
opportunity to identify independent predictors of early adverse outcomes as well as the risk 
of developing chronic DILI. However, the 6-month period used to define chronic DILI is 
somewhat arbitrary and some patients might still be recovering from the injury. Therefore, 
we are following all of the chronic DILI patients for 24 months after DILI onset to 
determine how often the liver injury abnormalities persist or resolve. A final limitation of 
our analysis is the assumption that there were no differences between the subjects with and 
without outcomes data. Sensitivity analyses, such as multiple imputation approach with 
assumption of data missing at random, could have been used to investigate the influence of 
missing data. However, our analyses suggested that the data is likely to be missing at 
random.
In conclusion, 9.4% of adult American patients with DILI either died or required liver 
transplantation within 6 months of DILI onset. A multitude of suspect drugs as well as 
various HDS products were implicated, both in subjects with early adverse outcomes and 
those who survived. However, Asian race, anti-neoplastic agents, and underlying lung 
disease were over-represented among subjects with an early adverse outcome. Chronic liver 
injury developed in 18.8% of the initial survivors, but was generally mild at 6 months of 
follow-up, and long-term outcomes will require additional study. African Americans, 
subjects with active malignancy, and those who presented with higher ALP and total 
bilirubin levels appeared to be at greatest risk for chronic DILI. Although our findings are 
exploratory, confirmation of these findings in other cohorts might allow for improved 
prognostication in individual patients and inform the design of future therapeutic trials in 
patients with clinically significant DILI.
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Overview of the study population.
*One subject died after liver transplant
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Kaplan–Meier Survival curves for time to each of the three early outcomes
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Table 1
Characteristics of Patients by 6-Month Outcome Status From Drug-Induced Liver Injury Onset
Featurea
Death or liver transplantation (n = 
62)
Alive with native liver at 6 months 
(n = 598) P value
Age, y, mean ± SD 53.0 ± 15.6 50.4 ± 15.9 .28
Female, % 58.1 59.7 .89
Race, % .01
 White 67.2 81.1
 Black 16.4 10.6
 Asian 9.8 2.5
 Others 6.6 5.9
Body mass index, mean ± SD 28.8 ± 7.0 27.8 ± 6.6 .19
Signs and symptoms at DILI onset, %
 Fever 29.0 27.1 .77
 Rash 17.7 27.8 .10
 Itching 27.4 58.5 <.01
Medical history, %
 Diabetes mellitus 43.5 23.4 <.01
 Heart disease 29.0 19.6 .10
 Kidney disease 22.6 11.5 .02
 Lung disease 29.0 16.9 .02
 Malignancy 27.4 8.5 <.01
 Active malignancy 17.7 3.8 <.01
 HIV+ 1.6 1.8 1
Self-reported drug allergies, % 58.1 44.6 .05
Pre-existing liver disease, %a 24.2 10.7 <.01
Prior alcohol use, % 46.7 52.5 .42
Implicated agents
 Medication use, d, median (range) 67 (2–3112) 31 (1–6971) .02
 Categories, % .98
  Single drug 56.5 55.7
  Single HDS 8.1 8.7
  Multiple drugs and/or HDS 35.5 35.6
 Primary implicated agent class, n (%) .97
  Antimicrobial 27 (43.5) 270 (45.2) .89
  HDS 10 (16.1) 98 (16.4) 1.00
  Cardiovascular 5 (8.1) 66 (11.1) .67
  Central nervous system 6 (9.7) 45 (7.5) .61
  Antineoplastic 7 (11.3) 28 (4.7) .04
  Analgesic 1 (1.6) 26 (4.4) .50
  Immunomodulatory 1 (1.6) 19 (3.2) .71
  Endocrine 1 (1.6) 14 (2.3) 1.00
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Featurea
Death or liver transplantation (n = 
62)
Alive with native liver at 6 months 
(n = 598) P value
  Rheumatologic 2 (3.2) 8 (1.3) .24
  Other 2 (3.2) 23 (3.9) 1.00
Laboratory parameters at DILI onset
 White blood cell count, 103/mm3, median (range) 7.9 (0.1–20.2) 6.3 (0.9–58.6) <.01
 Absolute eosinophil count, μL, median (range) 65 (0–1612) 147 (0–7420) <.01
  Eosinophils >500/μL, % 10.2 10.1 1.00
 Serum creatinine, mg/dL, median (range) 1.0 (0.5–7.3) 0.9 (0.1–7.6) <.01
 Antinuclear antibody+, % 32.8 28.2 .45
 Anti-Smith antibody+, % 25.9 20.6 .38
Liver biochemistries at DILI onset, median (range)
 Serum AST, U/L 1093 (76–4925) 287 (26–12,802) <.01
 Serum ALT, U/L 1051 (23–4212) 466 (14–15,065) <.01
 ALP, U/L 192 (94–1004) 220 (35–1952) .33
 Total bilirubin, mg/dL 9.5 (0.4–33.4) 4.9 (0.2–45.7) <.01
 INR 1.8 (0.9–6.2) 1.1 (0.8–12.2) <.01
 Albumin, g/dL 3.0 (1.1–4.2) 3.7 (1.0–5.8) <.01
 MELD score 24.0 (6.0–40.0) 16.0 (6.0–40.0) <.01
Hy’s law, %b 45.8 26.2 <.01
R value, median (range) 11.0 (0.2–82.4) 5.1 (0.1–426.2) <.01
Pattern of injury, % <.01
 Cholestatic 14.5 25.8
 Mixed 14.5 23.6
 Hepatocellular 71.0 50.7
Liver biochemistries at peak,c median (range)
 Peak serum AST, U/L 1494 (80–6924) 389 (45–12,802) <.01
 Peak serum ALT, U/L 1329 (70–5831) 558 (53–15,065) <.01
 Peak ALP, U/L 308 (119–2414) 281 (50–2865) .15
 Peak total bilirubin, mg/dL 25.9 (0.8–59.0) 9.1 (0.3–63.0) <.01
 Peak INR 3.4 (1.1–12.9) 1.1 (0.8–13.1) <.01
 Lowest albumin, g/dL 2.1 (0.9–3.5) 3.2 (0.4–4.9) <.01
 Peak R value 17.1 (0.5–210.4) 6.6 (0.3–426.2) <.01
Causality assessment score, n (%)c <.01
 Definite 13 (21.0) 167 (27.9)
 Very likely 26 (41.9) 315 (52.7)
 Probable 23 (37.1) 116 (19.4)
Steroid use, %c 82.0 36.6 <.01
Ursodeoxycholic acid use, %c 27.9 19.8 .14
DILIN severity score, n (%)c <.01
 Mild 2 (3.2) 150 (25.1)
 Moderate 2 (3.2) 147 (24.6)
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Featurea
Death or liver transplantation (n = 
62)
Alive with native liver at 6 months 
(n = 598) P value
 Moderate-hospitalized 2 (3.2) 187 (31.3)
 Severe 0 (0) 114 (19.1)
 Fatal/transplantation 56 (90.3) 0 (0)
HIV, human immunodeficiency virus; SD, standard deviation.
a
Per patient self-report. “Malignancy” refers to lifetime history of cancer and “active malignancy” delineates the subgroup of patients with a 
malignancy requiring treatment at the time of DILI onset.
b
Hy’s law criteria are subjects with ALT >3× ULN and total bilirubin >2.5 mg/dL at DILI onset with ALP <2× ULN.
c
Variables observed based on data from onset to the 6-month study visit. All other variables were either observed at DILI onset or at the baseline 
study visit, where the values would be similar to DILI onset.






















Fontana et al. Page 18
Table 2
Characteristics of Drug-Induced Livery Injury Patients Who Underwent Liver Transplantation or Died Within 
6 Months of Drug-Induced Liver Injury Onset
Characteristic
Liver transplant 
recipients (n = 30)
Liver-related death (n 
= 17)
Nonhepatic death (n = 
15) P valuea
Age, y, mean ± SD 47.0 ± 13.5 57.9 ± 15.3 59.7 ± 15.9 .02
Female, % 66.7 52.9 46.7 .38
Race, % .97
 White 62.1 76.5 66.7
 Black 17.2 11.8 20.0
 Asian 13.8 5.9 6.7
 Others 6.9 5.9 6.7
Body mass index, mean ± SD 29.7 ± 7.5 30.6 ± 6.7 24.7 ± 4.8 .04
Medical history, %
 Diabetes mellitus 33.3 52.9 53.3 .27
 Heart disease 20.0 23.5 53.3 .08
 Kidney disease 10.0 35.3 33.3 .06
 Lung disease 30.0 35.3 20.0 .67
 Malignancy 13.3 17.6 66.7 <.01
 Active malignancy 3.3 11.8 53.3 <.01
 HIV+ 3.3 0.0 0.0 1.00
 Self-reported drug allergies 53.3 58.8 66.7 .67
 Pre-existing liver disease 30.0 23.5 13.3 .51
 Prior alcohol use 66.7 20.0 33.3 <.01
Implicated agents
 Duration of primary agent use, d, median 
(range)
81 (2–2033) 57 (5–1707) 46 (3–3112) .60
 Categories, % .15
  Single drug 46.7 70.6 60.0
  Single HDS 16.7 0.0 0.0
  Multiple drug(s) and/or multiple HDS 36.7 29.4 40.0
 Primary implicated agent class, n (%) .42
  Antimicrobial 14 (46.7) 9 (52.9) 4 (26.7) .29
  HDS 8 (26.7) 1 (5.9) 1 (6.7) .17
  Antineoplastic 0 (0.0) 2 (11.8) 5 (33.3) <.01
  Central nervous system 3 (10.0) 1 (5.9) 2 (13.3) .87
  Cardiovascular 2 (6.7) 2 (11.8) 1 (6.7) .84
  Rheumatologic 1 (3.3) 0 (0.0) 1 (6.7) .73
  Analgesic 0 (0.0) 0 (0.0) 1 (6.7) .24
  Endocrine 1 (3.3) 0 (0.0) 0 (0.0) 1.00
  Gastrointestinal 1 (3.3) 0 (0.0) 0 (0.0) 1.00
  Other 0 (0.0) 2 (11.8) 0 (0.0) .13
Liver biochemistries at DILI onset
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Characteristic
Liver transplant 
recipients (n = 30)
Liver-related death (n 
= 17)
Nonhepatic death (n = 
15) P valuea
 Serum AST, U/L 1478 (254–4925) 556 (83–2644) 276 (76–1972) <.01
 Serum ALT, U/L 1354 (205–4212) 723 (23–2343) 375 (123–1895) <.01
 ALP, U/L 180 (94–688) 212 (108–942) 220 (101–1004) .51
 Total bilirubin, mg/dL 11.7 (0.6–30.0) 8.8 (0.4–27.5) 3.7 (0.5–33.4) .13
 INR 2.1 (1.7–3.9) 1.8 (1.0–6.2) 1.2 (0.9–3.6) .22
 Albumin, g/dL 3.2 (2.0–4.2) 2.9 (1.8–4.0) 2.8 (1.1–4.0) .27
 MELD score 30.0 (7.0–40.0) 22.0 (7.0–36.0) 21.0 (6.0–32.0) <.01
 Hy’s law, %b 63.0 35.3 26.7 .05
 R value 17.7 (1.6–82.4) 7.7 (0.2–27.6) 3.4 (0.9–41.3) <.01
 Pattern of injury, % <.01
  Cholestatic 3.3 29.4 20.0
  Mixed 0.0 5.9 53.3
  Hepatocellular 96.7 64.7 26.7
 Peak liver biochemistriesc
  Peak serum AST, U/L 1960 (655–6924) 1475 (170–3668) 377 (80–2500) <.01
  Peak serum ALT, U/L 1580 (551–5831) 1378 (70–2583) 504 (123–1895) <.01
  Peak ALP, U/L 296 (143–1051) 302 (136–2414) 672 (119–1484) .20
 Peak total bilirubin, mg/dL 26.3 (10.3–43.7) 31.5 (12.0–59.0) 17.1 (0.8–38.1) .05
  Peak INR 3.9 (2.0–12.9) 5.1 (1.4–12.0) 2.0 (1.1–4.7) <.01
  Lowest albumin, g/dL 2.1 (1.0–3.1) 2.1 (1.2–2.8) 2.0 (0.9–3.5) .88
  Peak MELD score 37.0 (15.0–40.0) 36.0 (21.0–40.0) 31.0 (11.0–34.0) <.01
  Peak R value 28.8 (8.1–210.4) 15.9 (0.5–38.3) 4.1 (1.0–41.5) <.01
 Causality score, n (%)c .79
  Definite 8 (26.7) 2 (11.8) 3 (20.0)
  Very likely 11 (36.7) 8 (47.1) 7 (46.7)
  Probable 11 (36.7) 7 (41.2) 5 (33.3)
Steroid use, %c 90.0 76.5 71.4 .23
Ursodeoxycholic acid use, %c 26.7 23.5 35.7 .81
HIV, human immunodeficiency virus; SD, standard deviation.
a
Comparisons made across 3 patient groups.
b
Hy’s law criteria are subjects with ALT >3× ULN and total bilirubin >2.5 mg/dL at DILI onset with ALP <2× ULN.
c
Variables observed based on data from onset to the 6-month study visit. All other variables were either observed at DILI onset or at the baseline 
study visit where the values would be similar to DILI onset.
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Table 3
Predictors for Time to Liver Transplantation or Liver-Related Death Within 6 Months of Drug-Induced Liver 
Injury Onset
Parameter
Univariate Cox regression probability model
Multivariate Cox regression probability model C-
statistic = 0.87 (95% CI: 0.82–0.93)
Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Race
 White Reference
 Black 1.65 (0.73–3.75) .231 0.82 (0.31–2.17) .688
 Asian 4.71 (1.83–12.1) <.01 3.18 (1.08–9.30) .035
 Other 1.34 (0.41–4.37) .63 0.52 (0.12–2.34) .398
Weight, kg 1.01 (0.999–1.02) .07
Body mass index 1.04 (1.00–1.08) .03
Itching 0.28 (0.15–0.54) <.01 0.33 (0.15–0.700) <.01
Diabetes/endocrine disorder 2.07 (1.15–3.70) .01
Pulmonary disease 2.21 (1.20–4.08) .01 2.86 (1.44–5.66) <.01
Family history of liver disease 2.39 (0.95–6.06) .07
ALT at onset, unit = 50 U/L 1.01 (1.01–1.02) <.01 1.01 (1.01–1.02) <.01
ALP at onset, unit = 50 U/L 0.93 (0.86–1.01) .09
Total bilirubin at onset, mg/dL 1.07 (1.04–1.10) <.01 1.10 (1.06–1.14) <.01
WBC at onset 1.05 (1.01–1.09) .01
Platelets at onset 0.99 (0.99–0.99) <.01 0.99 (0.99–0.997) <.01
Albumin at onset 0.36 (0.245–0.52) <.01 0.50 (0.33–0.76) <.01
Hy’s law 2.93 (1.62–5.29) <.01
NOTE. Predictors based on clinical information at onset or baseline selected by clinical input, univariate Cox regression with P value <.10, and 
with <50% missing data. Hazard ratio should be interpreted based on 1-unit increase unless otherwise indicated with a magnitude of unit increase.
SD, standard deviation; WBC, white blood cell.
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Table 4
Characteristics of Drug-Induced Liver Injury Subjects With and Without Chronic Drug-Induced Liver Injury 
at 6 Months After Drug-Induced Liver Injury Onset
Feature Chronic DILI (n = 113) Nonchronic DILI (n = 485) P value
Age, y, mean ± SD 49.7 ± 15.1 50.6 ± 16.1 .58
Female, % 67.3 57.9 .07
Race, % <.01
 White 73.5 82.9
 Black 18.6 8.7
 Asian 4.4 2.1
 Others 3.5 6.4
Body mass index, mean ± SD 27.6 ± 6.8 27.8 ± 6.5 .95
Signs and symptoms at DILI onset, %
 Fever 32.7 25.8 .16
 Rash 28.3 27.6 .91
 Itching 63.7 57.3 .24
Medical history, %
 Diabetes mellitus 28.3 22.3 .18
 Heart disease 23.9 18.6 .24
 Kidney disease 15.0 10.7 .19
 Lung disease 15.0 17.3 .68
 Malignancy 15.9 6.8 <.01
 Active malignancy 10.6 2.3 <.01
 HIV+ 2.7 1.6 .44
Self-reported drug allergies, % 41.6 45.4 .53
Pre-existing liver disease, % 13.3 10.1 .31
Prior alcohol use, % 46.4 53.9 .17
Implicated agents
 Duration of primary agent use, d, median (range) 51 (1–2343) 30 (1–6971) <.01
 Categories, % .34
  Single drug 50.4 56.9
  Single HDS 8.0 8.9
  Multiple drug(s) and/or multiple HDS 41.6 34.2
 Primary implicated agent class, n (%) .03
  Antimicrobial 41 (36.3) 229 (47.3) .04
  HDS 18 (15.9) 80 (16.5) 1.00
  Cardiovascular 14 (12.4) 52 (10.7) .62
  Psychotropic 5 (4.4) 40 (8.3) .23
  Antineoplastic 13 (11.5) 15 (3.1) <.01
  Analgesic 4 (3.5) 22 (4.5) .80
  Immunomodulatory 4 (3.5) 15 (3.1) .77
  Endocrine 5 (4.4) 9 (1.9) .16
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Feature Chronic DILI (n = 113) Nonchronic DILI (n = 485) P value
  Gastrointestinal 5 (4.4) 3 (0.6) <.01
  Other 4 (3.5) 19 (3.9) 1.00
Laboratory parameters at DILI onset
 WBC, 103/mm3, median (range) 6.2 (0.9–19.4) 6.4 (0.9–58.6) .87
 Absolute eosinophil count, μL, median (range) 173 (0.0–4501) 141 (0–7420) .14
  Eosinophils >500/μL, % 13.6 9.2 .22
 Serum creatinine,mg/dL, median (range) 0.8 (0.4–6.1) 0.9 (0.1–7.6) .45
  Antinuclear antibody+, % 29.4 28.0 .81
  Anti-Smith antibody+, % 24.3 19.7 .29
Liver biochemistries at DILI onset, median (range)
 Serum AST, U/L 285 (29–3107) 287 (26–12,802) .72
 Serum ALT, U/L 383 (14–3748) 482 (22–15,065) .10
 ALP, U/L 302 (41–1730) 208 (35–1952) <.01
 Total bilirubin, mg/dL 5.8 (0.2–36.2) 4.7 (0.2–45.7) .08
 INR 1.1 (0.9–3.5) 1.1 (0.8–12.2) .30
 Albumin, g/dL 3.6 (1.7–4.8) 3.8 (1.0–5.8) <.01
 MELD score 17.5 (6.0–40.0) 16.0 (6.0–39.0) .04
 R value 2.8 (0.1–76.2) 5.7 (0.2–426.2) <.01
Pattern of injury, % <.01
 Cholestatic 42.5 21.9
 Mixed 18.6 24.7
 Hepatocellular 38.9 53.4
Peak liver biochemistries,a median (range)
 Peak serum AST, U/L 389 (57–3229) 388 (45–12,802) .63
 Peak serum ALT, U/L 518 (62–3748) 574 (53–15,065) .22
 Peak ALP, U/L 467 (65–2865) 262 (50–2399) <.01
 Peak total bilirubin, mg/dL 13.7 (0.4–54.8) 7.9 (0.3–63.0) <.01
 Peak INR 1.2 (0.9–13.1) 1.1 (0.8–12.2) <.01
 Lowest albumin, g/dL 2.9 (0.6–4.9) 3.2 (0.4–4.8) <.01
 Peak MELD score 19 (6.0–40.0) 15 (6.0–40.0) <.01
 Peak R value 4.1 (0.3–111.3) 7.4 (0.4–426.2) <.01
Causality assessment score, n (%)a <.01
 Definite 19 (16.8) 148 (30.5)
 Very likely 61 (54.0) 254 (52.)
 Probable 33 (29.2) 83 (17.1)
Steroid use, %a 45.5 34.4 .04
Ursodeoxycholic acid use, %a 24.1 18.7 .23
DILIN severity score, n (%)a <.01
 Mild 19 (16.8) 131 (27.0)
 Moderate 21 (18.6) 126 (26.0)
 Moderate-hospitalized 41 (36.3) 146 (30.1)
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Feature Chronic DILI (n = 113) Nonchronic DILI (n = 485) P value
 Severe 32 (28.3) 82 (16.9)
 Fatal 0 (0) 0 (0)
HIV, human immunodeficiency virus; MELD, Model for End-Stage Liver Disease; SD, standard deviation; WBC, white blood cell count.
a
Variables observed based on data from onset to the 6-month study visit. All other variables were either observed at DILI onset or at the baseline 
study visit where the values would be similar to DILI onset.
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Table 5
Association Between Risk Factors and Chronic Drug-Induced Livery Injury Based on Logistic Regression
Parameter
Univariate probability model
Multivariate logistic regression probability model C-statistic = 
0.71 (95% CI: 0.65–0.76)
Odds ratio (95% CI) P value Odds ratio (95% CI) P value
Female 1.49 (0.97–2.30) .07
Race
 White Reference
 Black 2.42 (1.360–4.29) <.01 3.10 (1.68–5.72) <.01
 Asian 2.42 (0.81–7.25) .12 3.12 (0.95–10.22) .06
 Other 0.62 (0.21–1.81) .39 0.82 (0.28–2.43) .72
Malignancy
 No malignancy Reference
 Inactive malignancy 1.30 (0.51–3.29) .58 1.34 (0.47–3.83) .72
 Active malignancy 5.19 (2.22–12.1) <.01 6.37 (2.59–15.7) <.01
Duration of primary agent use 1.0 (1.0–1.001) .06
ALP at onset, unit = 50 U/L 1.07 (1.03–1.11) <.01 1.08 (1.04–1.12) <.01
Total bilirubin at onset, mg/dL 1.03 (0.999–1.06) .06
Hemoglobin at onset (±14 days) 0.83 (0.73–0.95) <.01
Albumin at onset (±14 days)a 0.64 (0.47–0.86) <.01
Heart disease
 No heart disease Reference
 Inactive heart disease 3.53 (1.50–8.32) <.01 3.36 (1.35–8.39) <.01
 Active heart disease 1.01 (0.57–1.80) .96 0.77 (0.40–1.49) .44
NOTE. Predictors based on demographic and clinical information at onset or baseline selected by clinical judgment, univariate logistic regression 
with P value <.10, and with <50% missing data. Odds ratio should be interpreted based on 1-unit increase unless otherwise indicated with a 
magnitude of unit increase. “Malignancy” refers to lifetime history of cancer and “active malignancy” delineates the subgroup of patients with a 
malignancy requiring treatment at the time of DILI onset. Similarly, “heart disease” refers to lifetime history of cardiac disease and “active heart 
disease” refers to subjects with a cardiac condition requiring treatment at the time of DILI onset.
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